Immix Biopharma’s Nexcella announces additional clinical data on NXC-201

Nexcella, a subsidiary of Immix Biopharma, announced that NXC-201 treatment continues to demonstrate 100% complete responses in a total of 6 relapsed/refractory AL amyloidosis patients. Clinical data published December 2022 in Clinical Cancer Research demonstrated 100% complete response rate; 100% organ response rate; NXC-201 Duration of Response Not Yet Reached at a median follow-up of 5.2 months, resulting in a mean 65% reduction in NT-proBNP from baseline; no grade 4 Cytokine Release Syndrome; no ICANS neurotoxicity was observed; a 2-stage improvement in NYHA stage was observed. Low-grade CRS duration of median 2 days with median onset on day 2 points to NXC-201 potentially becoming the first and only out-patient CAR-T to treat AL Amyloidosis and other BCMA-positive malignancies. "As we enroll additional patients, we continue to be encouraged by the consistent 100% complete response rate for AL amyloidosis patients treated with NXC-201 to-date," said Gabriel Morris, President, Nexcella, Inc. "We are heartened to provide hope for patients with this devastating disease in our ongoing efforts to bring NXC-201 to market." 4 patients with relapsed or refractory AL amyloidosis treated with NXC-201 were included in the December 2022 Clinical Cancer Research publication. 4 of 4 patients experienced a complete response and 4 of 4 patients experienced an organ response after treatment with NXC-201. 4 of 4 patients had cardiac involvement at the time of their baseline echocardiogram reading as defined by NT-proBNP levels. Treatment with NXC-201 resulted in a mean 65% reduction in mean NT-proBNP from baseline. Additionally, a 2-stage improvement in NYHA stage was observed after treatment with NXC-201